^
Association details:
| Biomarker: | EGFR exon 19 deletion + PD-L1 overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer
Published date:
06/04/2021
Excerpt:
A 61-year-old Asian man...pulmonary adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) gene….In January 2021, samples from the left upper lobe were biopsied; there was an exon 19 deletion, no T790M nutation, and PD-L1 TPS 80%...afatinib (40 mg/day) immediately after atezolizumab. The hilar mass markedly diminished 10 days after commencing afatinib (Figure 1(b)). Response has been sustained for more than 12 weeks.
DOI:
10.1111/1759-7714.14047
